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s Mitral Regurgitation
Viable Treatment
arget in Heart Failure?
he Plot Just Thickened*
andeep R. Mehra, MD, FACC,†
artley P. Griffith, MD‡
ew Orleans, Louisiana; and Baltimore, Maryland
he traditional cautious attitude towards surgical correction
f mitral regurgitation in the presence of severe left ventric-
lar failure recently has been vigorously challenged (1,2).
ecognition that mitral regurgitation occurs as part and
arcel of the cardiomyopathic state has focused attention
owards its amelioration as a viable therapeutic target.
everal observational studies have pointed out the high
revalence of significant mitral regurgitation in chronic
ystolic heart failure as well its association with a poor
ve-year survival (3–5). Thus, the notion that treatment
irected towards correcting the mitral valve could favorably
lter outcome in heart failure has been advanced. Some
esearchers have even advocated the use of such a surgical
pproach as an alternative to transplantation (6). Observa-
ional investigations by experienced surgical teams have
eported an improvement in symptoms and cardiac func-
ion. These results, however, suffer from lack of evaluation
f a control group.
See page 381
In this issue of the Journal, Wu et al. (7) present perhaps
he largest experience of mitral valve annuloplasty repair in
atients who have severe left ventricular dysfunction. The
rimary objective of this retrospective analysis was to ascer-
ain the effect of surgical annuloplasty on the end point of
ong-term mortality in patients. Using their echocardio-
raphic database, these investigators studied 682 patients
nd excluded those who did not meet criteria for surgical
ntervention (n  263). Of the remaining 419 patients, 126
nderwent mitral valve annuloplasty and 293 did not. No
mprovement in long-term survival (or the combined end
oint of mortality or urgent transplantation) was evident in
he surgical group, irrespective of heart failure etiology
either ischemic or nonischemic).
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Cardiovascular Medicine, Ochsner Clinic Foundation,d
ew Orleans, Louisiana; and the ‡Division of Cardiothoracic Surgery, University of
aryland at Baltimore, Baltimore, Maryland.Unfortunately, this observational investigation suffers
rom the classical limitation of “confounding by indication,”
hich the authors sought to overcome by developing a
ropensity score and using it in the Cox model multivariable
nalysis. The propensity score is the conditional probability
f exposure to a treatment given observed covariates. In a
ohort study, matching or stratifying treated and control
ubjects on a single variable, the propensity score, tends to
alance all of the observed covariates; however, unlike the
andom assignment of treatments, the propensity score also
ay not balance unobserved covariates. In the simplest
andomized experiment, the propensity score is 0.5 for every
atient. In contrast, in an observational study, without
andom assignment, the chance of being assigned to one
reatment or another may vary from patient to patient
epending on prognostic variables. Propensity scores re-
ove overt biases but do not account for hidden biases
ecause of unrecorded differences between treated and
ontrol patients (8).
Other limitations of this study include the single center
xperience (largely contributed to by a single surgeon); the
ack of follow-up on indices of ventricular structural remod-
ling; absence of any quantitative analysis of symptom or
unctional improvement; the inadequate control of appro-
riateness of medical therapy and, finally, little information
n the long-term durability of the repair. Despite these
nalytical limitations, this review calls into serious question
hat many clinicians now refer to as an “alternative or
ridge to transplantation” strategy. The reported five-year
vent-free survival is unaffected by whether the patients
uffered from an ischemic or nonischemic etiology of heart
ailure and is much lower than the known outcomes at this
ime point from cardiac transplantation (9). In Bolling’s
revious communications, he has stressed improvement in
ew York Heart Association functional class as a “winning”
utcome even if long-term outcomes might include the
eed for transplantation or less strikingly improved survival
1). The present report, however, does little to clarify the
mportant issue of possible symptomatic improvement.
natomy of the mitral valve. A normal mitral valve is
haracterized by apposition of the mitral valvular leaflet
oaptation point at the annular plane during systole. In
entricular dysfunction, this point of coaptation shifts to-
ards the ventricular apex (10). The ability to achieve
ppropriate leaflet coaptation is a function of a properly
ligned leaflet, an optimally sized annulus, and a geometri-
ally coordinated subvalvular apparatus (chordae tendinae
nd papillary muscles). Ventricular dysfunction is accompa-
ied by annular dilation, an increase in the interpapillary
uscle distance, amplified leaflet tethering, and decreased
losing forces (11). Assessment of all these aberrations is
ital because treatment options that attend to only one
spect are likely to lead to partial benefits. Although the
eport of Wu et al. (7) does not provide information on the
urability of the repair, we know that annuloplasty alone for
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February 1, 2005:388–90 Editorial Commentschemic mitral regurgitation may be associated with recur-
ence of2 mitral regurgitation in as many as a one-third
f patients (12).
harmacologic and cardiac resynchronization therapy
ffects on mitral regurgitation. The treatment of heart
ailure has evolved from the neurohormonal model to
evices that attempt to resynchronize focal areas of discor-
ant contractility (13). Thus, pharmacological treatment
ith beta-blockers diminishes mitral regurgitation by favor-
ble ventricular remodeling (14–16). Similarly, in the set-
ing of decompensated heart failure, vasodilator therapy
nhances forward stroke volume by decreasing mitral regur-
itant fraction and reducing the mitral valve orifice area
17). However, cardiac resynchronization therapy improves
itral regurgitation by improving ventricular asynergy (18–
0). This benefit is related to an increase in mitral valve
losing forces generated by resynchronization therapy (19).
hese lines of evidence point to the importance of optimi-
ation of medical and nonsurgical device intervention in
reating mitral regurgitation before surgery is entertained.
urgical aspects of mitral valve repair. Although an
undersized” annuloplasty repair is believed to effectively
orrect mitral regurgitation in heart-failure patients, ques-
ions of its durability remain. Recurrent mitral leak is often
ue to progressive lateral displacement of the papillary
uscles and attendant chordal tethering (12). Severe dis-
lacement of the anterior muscle may be predictive of
ecurrence. From a surgeon’s viewpoint, it is critical to plan
he operative approach by being anatomically well informed.
his includes knowledge of the presence of leaflet malco-
ptation (failure to meet), malapposition (failure to close at
he same plane), annulus diameter, interpapillary distance,
nd chordal length. The mode of repair selected must then
ddress these multiple aberrations. This is why, some argue,
hat functional ischemic mitral regurgitation cannot be
reated adequately with annuloplasty (12,21).
In the remodeled ventricle, the papillary muscle tethering
istance and angle must also be rectified. Menicanti et al.
22), on behalf of the RESTORE surgical remodeling
roup, has emphasized intraventricular imbrication or
pexy” to realign displaced papillary muscles. Kron et al. (23)
ave surgically relocated the posterior papillary muscle in
hronic ischemic mitral regurgitation. However, others have
emonstrated the efficacy of secondary chordal cutting to
able 1. Effects of Various Treatments on Mitral Regurgitation i
Intervention Speci
Global” therapy (directed at the primary disease process) ACE inhibito
Beta-blockers
Focused” therapy (directed at the mitral valve)
Percutaneous CRT
Surgical MVA
xperimental CS annular c
Cardiac passi
CE  angiotensin-converting enzyme; CRT  cardiac resynchronization therapy;elieve the tethering caused by papillary muscle displace-ent (24). Moainie et al. (25) have demonstrated that
xternal infarct restraint attenuates remodeling and mitral
egurgitation in an ovine model of posterior lateral infarc-
ion. Ongoing surgical clinical trials evaluating cardiac
estraint devices with and without correction of mitral
egurgitation are underway and should provide important
nformation about this approach (26). Finally, lest interven-
ional cardiologists fear they may remain idle while surgical
ptions evolve, we know that percutaneous options are
eing assessed as well (27,28). Although these percutaneous
ptions are not likely to improve beyond simple annulo-
lasty, they might help advance the field with tandem
rocedures such as adjunctive minimally invasive application
f external restraint devices.
Although the investigation of Wu et al. (7) suggests that
atients receive little benefit from mitral valve annuloplasty,
everal questions are raised. Is this lack of benefit because
itral valve surgery does not work or because a different
urgical approach is needed? Is annuloplasty sufficient? Are
ubannular three-dimensional repairs required? We simply
o not know. As Wu et al. (7) admit, only well-designed,
andomized controlled trials will answer these issues with
nality. Until then, what is a clinician to do? First, we
elieve that pharmacological options, including widespread
nd aggressive neurohormonal inhibition and use of vaso-
ilators should be employed when indicated. Device therapy
cardiac resynchronization) should also be used in appropri-
tely selected candidates (Table 1). If surgery is considered
s an alternative to transplantation, the patient should be
nformed of the uncertainties of the outcome with this
pproach. We strongly believe that a randomized clinical
rial is feasible and endorse the development of registries
hat systematically evaluate surgical outcomes from this
pproach.
eprint requests and correspondence: Dr. Mandeep R. Mehra,
514 Jefferson Highway, New Orleans, Louisiana 70121. E-mail:
mehra@Ochsner.org.
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